Moderna continued to hit new highs.
Earnings beat expectations. On 11/09, it reached an intraday high of $280.8, a 52-week high, and closed at $269, up 5.8%. A year ago, it was still at $22; in September, it was around $140.
Last week, I said this pharma-led rally had entered its third phase: immersed in pharma. The main theme is simple and hasn’t changed.
$MRNAON
Earnings beat expectations. On 11/09, it reached an intraday high of $280.8, a 52-week high, and closed at $269, up 5.8%. A year ago, it was still at $22; in September, it was around $140.
Last week, I said this pharma-led rally had entered its third phase: immersed in pharma. The main theme is simple and hasn’t changed.
$MRNAON